Social Vulnerability: A New Risk Stratifier for Liver and Heart Outcomes in Fatty Liver Disease
A large retrospective cohort study has quantified the significant impact of documented social vulnerability on clinical outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Using a U.S.-wide electronic health records network, researchers compared patients with MASLD and ICD-10 codes for social vulnerability—such as extreme poverty, low income, or social exclusion—to those without such documentation. Over a five-year follow-up, socially vulnerable individuals faced a substantially higher risk of major adverse liver outcomes (MALO) and major adverse cardiovascular events (MACE). Specifically, the risk of MALO was 1.69 times higher, and the risk of MACE was 1.64 times higher. The incidence of arrhythmias and heart failure was also significantly elevated, though the risk for hepatocellular carcinoma (HCC) did not differ between the groups.
Why it might matter to you: This research provides robust, data-driven evidence that social determinants are critical independent predictors of hard clinical endpoints in MASLD, moving beyond traditional metabolic risk factors. For hepatology practice, it underscores the necessity of systematically screening for and integrating social vulnerability into risk prediction models like the MELD score. Addressing these non-medical factors could be essential for developing more equitable and effective management strategies to reduce disparities in liver-related and cardiovascular morbidity.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
